Pular para o conteúdo principal
Ranking Invest

IPHA - Innate Pharma S.A.

Segmento: HealthcareInnate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Análise Ranking Invest

Valor de Mercado
$ 169.78 Mi
IVR
-1.55Índice proprietário de comparação relativa: -1,55.
IVR2
-1.62Leitura proprietária complementar: -162%.
MLL
-1.62Leitura proprietária complementar: -162%.
Último Balanço Atualizado: 4T2024

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 8.83 Mi

Dívida Líquida

-$ 35.40 Mi

L4T

-$ 57.04 Mi

MM4T

-2297.72%

Indicadores Básicos

ROE

-645.70%

Índices de Previsibilidade

Receita Líquida

F0.58

Lucro

D0.92

Margem

D0.90

Índices de Tendência

Receita Líquida

E-4.92

Lucro

E-1.78

Margem

E-3.35

Índices de Endividamento

DIV/PAT

-4.01

DIV/L4T

0.62

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.